Portal Home For reimbursement information regarding other Centocor Ortho Biotech Inc. products, please click here.
PROCRITline.com Reimbursement Excellence Centocor Ortho Biotech Inc.
Introduction Commercial Payer Prior Authorization Medicare Part D Prior Authorization Please see full Prescribing Information, including Boxed WARNINGS, for PROCRIT® (Epoetin alfa) Medicare Guideline Archives Medicare Guideline Update Table CMS 1450 / UB-04

State Medicare Guidelines / CMS 1500
Select



State Medicare Guidelines / CMS 1500

Idaho Printable Version


Summary - Part A  Summary - Part B  

National Coverage Determination

Local Coverage Determinations / Supporting Documentation:
Part A - Part B

CMS 1500 Examples
Initial Claims: Oncology 1 Subsequent Claims: Oncology 2
Nephrology 1 Nephrology 2
AZT/HIV 1 AZT/HIV 2
Surgery 1 Surgery 2
Payers

Part-A
Noridian Administrative Services / National Heritage Insurance Company (MAC)

Part-B
Cigna Government Services / National Heritage Insurance Company (MAC)

Carrier/FI/MAC Changes




Please refer to the National Coverage Determination (NCD) for additional information that may supercede the Medicare guidelines provided by your local Medicare Carrier, Fiscal Intermediary, or Medicare Administrative Contractor (MAC).



Summary - Part A - Updated December 16, 2009

For additional information on Medicare covered indications for your specific state, please see the appropriate Part A Local Coverage Determinations/Supporting Documentation which may be accessed through the link above or by
clicking here - Part A.

Your state has two Medicare contractors which process claims for Part A providers. If you use WPS (formerly Mutual of Omaha), please select it now. WPS If you do not use WPS, the Medicare guideline summary is below.

Indication ICD-9-CM HCPCS Starting Labs Ending Labs GFR/Serum Creatinine Allowable Dosage Post Chemo
Cancer (chemo) 285.3 and V67.2 or V58.11
Link
J0885
Link
Not Stated
Link
Not Stated SC: Not Applicable

GFR: Not Applicable
Not Stated Not Stated
AIDS/AZT 285.9 and 042
Link
J0885
Link
HCT < 30% w/in one wk of initial treatment & anemia must be symptomatic
Link
Hb 12 g/dL or HCT 36%
Link
SC: Not Applicable

GFR: Not Applicable
Per FDA
Link
Not Applicable
Renal 285.21 and 403.01, 403.11, 403.91, 404.02, 404.03, 404.12, 404.13, 404.92, 404.93, 585.3, 585.4, 585.5, 585.9 or V42.0
Link
J0885
Link
HCT < 30% w/in one wk of the initial injection, or higher if anemia is symptomatic
Link
HCT 36%
Link
SC: Not Stated

GFR: GFR < 60 mL/min/1.73m^2
Link
Not Stated Not Applicable
Surgery (hip or knee) 284.81, 284.89, 284.9, 285.21, 285.22, 285.29, 285.8, or 285.9 and V07.8
Link
J0885
Link
Hb between 10 and 13 g/dL w/in one wk of initial injection
Link
Not Stated SC: Not Applicable

GFR: Not Applicable
Not Stated Not Applicable

These summaries have been prepared using the Medicare guidelines. If you would like to receive the Medicare guidelines, you can call PROCRITline® at 1-800-553-3851 or you can contact the Medicare contractor directly at the web address in the State Medicare Payers box above.
R138
Back to Top



Please refer to the National Coverage Determination (NCD) for additional information that may supercede the Medicare guidelines provided by your local Medicare Carrier, Fiscal Intermediary, or Medicare Administrative Contractor (MAC).



Summary - Part B - Updated October 01, 2009

For additional information on Medicare covered indications for your specific state, please see the appropriate Medicare carrier Part B Local Coverage Determinations/Supporting Documentation which may be accessed through the link above or by
clicking here - Part B.

Indication ICD-9-CM HCPCS Starting Labs Ending Labs GFR/Serum Creatinine Allowable Dosage Post Chemo
Cancer (chemo) 285.3. Or, V58.11 and malignancy code
Link
J0885
Link
HCT < 30% or Hb < 10 g/dL
Link
HCT 30%
Link
SC: Not Applicable

GFR: Not Applicable
Recommended starting dose 150 U/kg 3x/wk
Link
8 weeks
Link
AIDS/AZT 042
Link
J0885
Link
HCT < 33%; endogenous serum EPO < 500 mU/mL prior to therapy.
Link
Link
HCT 36%. For HCT > 34%+/- 2%, retain documentation to support necessity in medical record.
Link
SC: Not Applicable

GFR: Not Applicable
Usual dose 40,000 units in single or divided doses, maximum dose 60,000 units in single or divided doses.
Link
Not Applicable
Renal 285.21 and 585.2, 585.3, 585.4, 585.5 or 585.9
Link
J0885
Link
HCT < 33%
Link
HCT 36%. Or, for HCT > 34%+/- 2%, retain documentation to support necessity in medical record.
Link
SC: Most recent serum creatinine or estimated creatinine clearance within the last month. Values not stated.
Link

GFR: Not Stated
Usual dose 40,000 units in single or divided doses, maximum dose 60,000 units in single or divided doses.
Link
Not Applicable
Surgery (elective, non-cardiac, non-vascular) V72.83 and condition for which the patient is undergoing surgery
Link
J0885
Link
HCT < 33%
Link
HCT 36%. Or, for HCT > 34%+/- 2%, retain documentation to support necessity in medical record.
Link
SC: Not Applicable

GFR: Not Applicable
Usual dose 40,000 units/wk given in single or divided doses. Maximum dose 60,000 units/wk in single or divided doses.
Link
Not Applicable

These summaries have been prepared using the Medicare guidelines. If you would like to receive the Medicare guidelines, you can call PROCRITline® at 1-800-553-3851 or you can contact the Medicare contractor directly at the web address in the State Medicare Payers box above.
R135
Back to Top